ViaCyte, Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Novocell, Inc. (to 2011)
Previously recorded as Cythera, Inc. (to 2012)
71
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for Cryopreserved in vitro cell culture of human pancreatic progenitor cells (US 11,660,377) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Dec 2, 2026The maintenance fee for Methods for enriching for pancreatic endocrine cells (US 9,045,736) comes due Dec 2, 2026. Unpaid by Jun 2, 2027, it lapses early.
- 4 fees due Feb 6 to 27, 2027 · next Feb 6
- 1 fee due Mar 15, 2027The maintenance fee for Encapsulation of pancreatic cells derived from human pluripotent stem cells (US 9,132,226) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 3 fees due Aug 13 to 20, 2027 · next Aug 13
- 2 fees due Sep 5 to 12, 2027 · next Sep 5
Recent changes
- 2 of the patents on this record were granted since Aug 24, 2026
- Nov 3 US 12,779,403 A Biocompatible Membrane Composite
- Nov 3 US 12,778,704 Tools and Instruments for Use with Implantable Encapsulation Devices
- 3 terms have ended since Aug 24, 2026
- Oct 27 US 9,499,795 PDX1-expressing dorsal and ventral foregut endoderm · term ended
- Oct 27 US 11,427,805 Methods of producing human foregut endoderm cells expressing PDX1 from human definitive endoderm · term ended
- Oct 13 US 11,746,323 PDX1 positive foregut endoderm cells and methods of production · term ended
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,415,158 | Compositions and methods useful for culturing differentiable cells In force · USPTO record | In force | USPTO record | |
| US 8,658,352 | Compositions and methods useful for culturing differentiable cells In force · USPTO record | In force | USPTO record | |
| US 8,633,024 | PDX1 expressing endoderm In force · USPTO record | In force | USPTO record | |
| US 7,534,608 | Methods of producing pancreatic hormones In force · USPTO record | In force | USPTO record | |
| US 7,993,920 | Methods of producing pancreatic hormones In force · USPTO record | In force | USPTO record | |
| US 8,603,811 | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production In force · USPTO record | In force | USPTO record | |
| US 10,517,901 | Methods of lowering blood glucose levels in a mammal In force · USPTO record | In force | USPTO record | |
| US 8,586,357 | Markers of definitive endoderm In force · USPTO record | In force | USPTO record | |
| US 9,980,986 | Methods of producing pancreatic hormones In force · USPTO record | In force | USPTO record | |
| US 8,574,905 | Hepatocyte lineage cells In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 96: 1 patent in force now held by others · 9 lapsed for an unpaid fee · 17 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
9 pending · 4 abandoned · 20 no status recorded
Showing 1 to 10 of 33, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/190,312 | Biocompatible Membrane Composite | Apr 25, 2025 | Pending |
| 19/091,441 | Mar 26, 2025 | No status recorded | |
| 18/911,505 | PDX1 Pancreatic Endoderm Cells in Cell Delivery Devices and Methods Thereof | Oct 10, 2024 | Pending |
| 18/885,643 | Modulating Inflammation Associated with Foreign Body Response | Sep 14, 2024 | Pending |
| 18/662,902 | Endocrine Cells That Express Chromogranin A | May 13, 2024 | Abandoned |
| 18/416,646 | Cell Encapsulation Device Comprising a Pancreatic Progenitor Cell Population | Jan 18, 2024 | Pending |
| 19/116,532 | Implantable Membrane Construct and Encapsulation Devices Incorporating the Same | Sep 29, 2023 | Pending |
| 19/115,902 | Anchor Regions for Implantable Medical Device | Sep 29, 2023 | Pending |
| 18/373,014 | Sep 26, 2023 | No status recorded | |
| 18/138,904 | Apr 25, 2023 | No status recorded |
10 of 33 applications shown.
Pro members see all 33 published applications.